93 related articles for article (PubMed ID: 7538899)
1. Does pregnancy immunize against breast cancer?
Agrawal B; Reddish MA; Krantz MJ; Longenecker BM
Cancer Res; 1995 Jun; 55(11):2257-61. PubMed ID: 7538899
[TBL] [Abstract][Full Text] [Related]
2. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients.
Kotera Y; Fontenot JD; Pecher G; Metzgar RS; Finn OJ
Cancer Res; 1994 Jun; 54(11):2856-60. PubMed ID: 7514493
[TBL] [Abstract][Full Text] [Related]
3. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors.
Agrawal B; Reddish MA; Longenecker BM
J Immunol; 1996 Sep; 157(5):2089-95. PubMed ID: 8757331
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.
Ioannides CG; Fisk B; Jerome KR; Irimura T; Wharton JT; Finn OJ
J Immunol; 1993 Oct; 151(7):3693-703. PubMed ID: 7690810
[TBL] [Abstract][Full Text] [Related]
5. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens.
Apostolopoulos V; Xing PX; McKenzie IF
Cancer Res; 1994 Oct; 54(19):5186-93. PubMed ID: 7923138
[TBL] [Abstract][Full Text] [Related]
6. Induction of antibody responses to breast carcinoma associated mucins using synthetic peptide constructs as immunogens.
Denton G; Sekowski M; Price MR
Cancer Lett; 1993 Jul; 70(3):143-50. PubMed ID: 7689035
[TBL] [Abstract][Full Text] [Related]
7. Human B cell immune response to selected epitopes of the polymorphic epithelial mucin (PEM) in cancer patients.
Nuti M; Rughetti A; Turchi V; Apollonj-Ghetti C; Scambia G; Frati L
In Vivo; 1993; 7(6B):645-7. PubMed ID: 7514896
[TBL] [Abstract][Full Text] [Related]
8. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.
Tuttle TM; Anderson BW; Thompson WE; Lee JE; Sahin A; Smith TL; Grabstein KH; Wharton JT; Ioannides CG; Murray JL
Clin Cancer Res; 1998 Aug; 4(8):2015-24. PubMed ID: 9717833
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer associated mucin: a review.
Segal-Eiras A; Croce MV
Allergol Immunopathol (Madr); 1997; 25(4):176-81. PubMed ID: 9269507
[TBL] [Abstract][Full Text] [Related]
10. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
11. The mucin antigens: what are we measuring?
Price MR; Briggs S; Scanlon MJ; Tendler SJ; Sibley PE; Hand CW
Dis Markers; 1991; 9(3-4):205-12. PubMed ID: 1725974
[TBL] [Abstract][Full Text] [Related]
12. Recombinant MUC 1 vaccinia virus: a potential vector for immunotherapy of breast cancer.
Balloul JM; Acres RB; Geist M; Dott K; Stefani L; Schmitt D; Drillien R; Spehner D; McKenzie I; Xing PX
Cell Mol Biol (Noisy-le-grand); 1994; 40 Suppl 1():49-59. PubMed ID: 7950862
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA.
Jerome KR; Domenech N; Finn OJ
J Immunol; 1993 Aug; 151(3):1654-62. PubMed ID: 8393050
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma.
Goydos JS; Elder E; Whiteside TL; Finn OJ; Lotze MT
J Surg Res; 1996 Jun; 63(1):298-304. PubMed ID: 8667619
[TBL] [Abstract][Full Text] [Related]
15. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
[TBL] [Abstract][Full Text] [Related]
16. Human B-cell immune response to the polymorphic epithelial mucin.
Rughetti A; Turchi V; Ghetti CA; Scambia G; Panici PB; Roncucci G; Mancuso S; Frati L; Nuti M
Cancer Res; 1993 Jun; 53(11):2457-9. PubMed ID: 8495404
[TBL] [Abstract][Full Text] [Related]
17. Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-1 mucin gene.
Dahiya R; Kwak KS; Byrd JC; Ho S; Yoon WH; Kim YS
Cancer Res; 1993 Mar; 53(6):1437-43. PubMed ID: 8443822
[TBL] [Abstract][Full Text] [Related]
18. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
19. Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides.
Fagerberg J; Askelöf P; Wigzell H; Mellstedt H
Cell Immunol; 1999 Sep; 196(2):110-21. PubMed ID: 10527563
[TBL] [Abstract][Full Text] [Related]
20. Peptide epitopes in breast cancer mucins.
Xing PX; Apostolopoulos V; Trapani J; Prenzoska J; McKenzie IF
Adv Exp Med Biol; 1994; 353():9-16. PubMed ID: 7527180
[No Abstract] [Full Text] [Related]
[Next] [New Search]
